Harvard Bioscience, Inc.
HBIO
$0.38
-$0.0099-2.54%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 24.56M | 21.97M | 23.10M | 24.51M | 28.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.56M | 21.97M | 23.10M | 24.51M | 28.15M |
| Cost of Revenue | 10.50M | 9.21M | 9.88M | 9.74M | 11.51M |
| Gross Profit | 14.05M | 12.77M | 13.22M | 14.77M | 16.65M |
| SG&A Expenses | 10.01M | 10.56M | 11.08M | 11.87M | 11.23M |
| Depreciation & Amortization | 1.26M | 1.33M | 1.33M | 1.33M | 1.39M |
| Other Operating Expenses | 0.00 | -- | -147.00K | 966.00K | -- |
| Total Operating Expenses | 24.10M | 23.67M | 24.77M | 26.79M | 27.27M |
| Operating Income | 459.00K | -1.70M | -1.67M | -2.28M | 883.00K |
| Income Before Tax | 590.00K | -4.49M | -3.28M | -4.48M | -1.10M |
| Income Tax Expenses | 572.00K | 311.00K | -353.00K | 210.00K | 715.00K |
| Earnings from Continuing Operations | 18.00K | -4.80M | -2.93M | -4.69M | -1.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.00K | -4.80M | -2.93M | -4.69M | -1.82M |
| EBIT | 459.00K | -1.70M | -1.67M | -2.28M | 883.00K |
| EBITDA | 2.22M | 120.00K | 128.00K | -498.00K | 2.66M |
| EPS Basic | 0.00 | -0.11 | -0.07 | -0.11 | -0.04 |
| Normalized Basic EPS | 0.04 | -0.06 | -0.04 | -0.06 | 0.00 |
| EPS Diluted | 0.00 | -0.11 | -0.07 | -0.11 | -0.04 |
| Normalized Diluted EPS | 0.03 | -0.06 | -0.04 | -0.06 | 0.00 |
| Average Basic Shares Outstanding | 43.66M | 43.61M | 43.49M | 43.40M | 42.71M |
| Average Diluted Shares Outstanding | 44.45M | 43.61M | 43.49M | 43.40M | 42.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |